CG Oncology Exceeds Even The 'Most Bullish Conversations;' Shares Break Out

Resumen detallado
CG Oncology said Monday its experimental bladder cancer treatment cut the risk of recurrence by 68%. The biotech stock broke out. The post CG Oncology Exceeds Even The 'Most…
CG Oncology (CGON) said Monday its experimental bladder cancer treatment cut the risk of recurrence by 68%. The news sent the biotech stock flying into breakout territory. "We see these results as meaningfully exceeding both the powering expectations (~30%) and investor expectations (~40%), and even in our most bullish conversations we did not hear investors expect a risk reduction greater…
Inicio del artículo, extracto de Investor's Business Daily. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.investors.com)